# EVOLVE-1 (venetoclax): what one clinician is saying

> 27 statements from 6 sources (1 podcast, 2 videos, 3 posts), 2 of them from 1 confirmed clinician, each linked to its source. Commentary checked Nov 21, 2026.

## Report

- Trial: Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
- NCT ID: NCT07075016
- Registry: https://clinicaltrials.gov/study/NCT07075016
- Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland
- Phase: Phase 3
- Status: Recruiting
- Drugs tested: venetoclax
- Indication: IDH1-mutated AML or MDS/AML ineligible for intensive chemotherapy
- Version: v1.0.0, edition 1
- Accepted: 2026-11-21 UTC
- Last checked: 2026-11-21 UTC
- Release hash: bb638d6d5b162313c6f21ee17a94a2a886aa51c2d6ee0dc774c877672757a701

## Counts

- Commentary sources screened: 14
- Sources cited by verified statements: 6
- Verified statements: 27
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 2
- Findings: 6
- Named people in screened sources (unnamed speakers and accounts not counted): 4
- Speakers cited: 4
- Cited speakers with a verified identity: 3
- Cited clinicians, speakers with a confirmed clinical role (the abstract's clinicians): 1
- Of them physicians, whose confirmed role is a physician's, not a physician assistant's, nurse's or pharmacist's (the abstract's physicians): 1
- By role and specialty (the abstract's specialty counts):
  - 1 physician, specialty not confirmed
- Organisational or shared accounts (not counted as people): 2

A verified identity says who a speaker is. A cited clinician also has a clinical role confirmed by the NPI registry or their own institution's staff page. Verified speakers without such a role, such as researchers, advocates, company staff, or clinicians whose role only a source or their own profile states, are not counted as clinicians.

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

Speakers support EVOLVE-1 on the basis of earlier triplet responses, while one speaker requires randomized phase III confirmation. That speaker also regards ivosidenib/azacitidine as standard care, framing the distinction between a rationale for testing venetoclax and evidence for its routine addition. Favorable tolerability impressions do not establish comparable safety, and the sources reviewed for this edition report no randomized benefit or safety outcomes.

## Findings (titles)

- F1. Phase Ib/II triplet: a speaker highlights activity but needs phase III RCTs
  - 11 statements from 3 speakers in 4 sources, 3 of them podcasts or videos.
  - 1 of the 3 named speakers in this finding holds this view; 1 of them holds its caveat, “need phase III RCTs”.
  - No named clinician · accounts and unnamed speakers.
- F4. EVOLVE-1 recruitment: what a speaker hopes for in local AML care
  - 2 statements in 1 source.
  - No named speaker is counted in this finding: its title's view comes from speakers the source does not name.
  - No named clinician · accounts and unnamed speakers.

### Beyond the trial population

- F2. Older AML on LIT: what speakers say
  - 7 statements from 1 speaker in 2 sources, all podcasts or videos.
  - No named clinician · accounts and unnamed speakers.
- F3. Early-phase triplet safety: what speakers say
  - 5 statements from 2 speakers in 3 sources, 2 of them podcasts or videos.
  - No named clinician · accounts and unnamed speakers.
- F5. IDH-mutated AML triplets: what a speaker highlights in response depth
  - 1 statement in 1 source.
  - No named speaker is counted in this finding: its title's view comes from speakers the source does not name.
  - No named clinician · accounts and unnamed speakers.
- F6. AML triplets: a clinician seeks durability but notes venetoclax's limits
  - 4 statements from 2 speakers in 1 source, a podcast or video.
  - 1 of the 2 named speakers in this finding holds this view, a confirmed clinician; 1 of them holds its caveat, “note venetoclax's limits”.
  - 1 of the report's 1 cited clinicians.

4 of the 6 findings and 14 of the 27 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding. Speakers are the named people a finding's statements cite, of any role, counted as the report counts its cited speakers; unnamed speakers and accounts are not counted.

| Finding | Statements | Passages | Sources | Speakers | Limitations |
| --- | ---: | ---: | ---: | ---: | ---: |
| F1 | 11 | 6 | 4 | 3 | 3 |
| F4 | 2 | 1 | 1 | 0 | 2 |
| F2 | 7 | 3 | 2 | 1 | 2 |
| F3 | 5 | 4 | 3 | 2 | 3 |
| F5 | 1 | 1 | 1 | 0 | 3 |
| F6 | 4 | 3 | 1 | 2 | 2 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Statement links to supporting passages | Statement links to context passages | Sources by kind |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- |
| F1 | 7 | 0 | 0 | 0 | 4 | 13 | 2 | 1 post or article, 3 podcasts and video |
| F4 | 1 | 0 | 1 | 0 | 0 | 2 | 0 | 1 post or article |
| F2 | 3 | 0 | 0 | 0 | 4 | 8 | 1 | 2 podcasts and video |
| F3 | 0 | 0 | 0 | 1 | 4 | 7 | 0 | 1 post or article, 2 podcasts and video |
| F5 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 post or article |
| F6 | 4 | 0 | 0 | 0 | 0 | 4 | 0 | 1 podcast or video |

### Trial dimensions

- Primary endpoint: Event-free survival (EFS) in patients with newly diagnosed IDH1-mutated AML ineligible for intensive chemotherapy: no finding draws on it directly
- Secondary endpoints: no finding draws on it directly
- Population and setting: F1 (2 shared claims)
- The comparison: F1 (5 shared claims)
- Safety and tolerability: F1 (2 shared claims), F4 (1 shared claims)
- Design and conduct: F1 (2 shared claims), F4 (1 shared claims)

## Abbreviations

- EFS: event-free survival
- HCP: healthcare professional
- MCP: Model Context Protocol, how AI agents read the report
- MRD: measurable residual disease
- NPI: National Provider Identifier, the US registry number for clinicians
- RCT: randomized controlled trial

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 6 | Titles free |
| Detailed analysis | 8 sections | Paid |
| Verified statements with short source quotes and links | 27 | Paid |
| Who said each statement: the cited speakers | 4 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 1 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 3 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 10 | Free |
| Sources with links | 6 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |

Every edition, the free report included, names who said each statement, as the source shows them. Each named speaker's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 1 of the 4 cited speakers have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key, and with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself. Social accounts are not included. The IDs are for checking attribution inside your organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.

## Trial aspects

9 discussed · 1 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Event-free survival (EFS) in patients with newly diagnosed IDH1-mutated AML ineligible for intensive chemotherapy | no commentary found | 0 | 0 |
| Secondary endpoints | discussed | 1 | 1 |
| Population and setting | discussed | 4 | 3 |
| The comparison (The registered arms and what clinicians said about how they compare.) | discussed | 7 | 4 |
| Safety and tolerability | discussed | 6 | 4 |
| Design and conduct | discussed | 4 | 4 |
| Doublet positioning and the missing head-to-head comparison | discussed | 7 | 2 |
| Earlier triplet evidence and limits of extrapolation | discussed | 9 | 4 |
| Residual unmet need and conditional hopes for molecularly selected triplets | discussed | 4 | 1 |
| Local recruitment and anticipated patient benefit | discussed | 2 | 1 |

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

## Sources

| Channel | Statements | Cited | Screened |
| --- | ---: | ---: | ---: |
| **Video & audio · 21 statements · 78%** | | | |
| YouTube | 16 | 2 | 2 |
| Podcasts | 5 | 1 | 2 |
| **Posts · 6 statements · 22%** | | | |
| X threads | 6 | 3 | 10 |

- Screened window: 2025-05-23 to 2026-10-16
- Cited window: 2025-05-23 to 2026-10-16
- Retrieved: 2026-11-21

Statements count each verified statement once, split evenly over the sources it cites. Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
- Registry: NCT07075016 (https://clinicaltrials.gov/study/NCT07075016)
- Study IDs: HO173 · 2024-512753-24
- Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland
- Collaborators: German-Austrian Acute Myeloid Leukemia Study Group, United Kingdom AML Research Network, Gruppo Italiano Malattie EMatologiche dell'Adulto, Swiss Group for Clinical Cancer Research (SAKK), Danish Acute Leukemia Group, Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias, Nordic AML Group
- Design: Phase 3 · interventional, randomized, single group, phase3
- Status: Recruiting
- Enrollment: 227 (estimated)
- Start: 2025-08-05 (actual)
- Primary completion: 2028-12 (estimated)
- Primary endpoint: Event-free survival (EFS) in patients with newly diagnosed IDH1-mutated AML ineligible for intensive chemotherapy (12 months after inclusion of last AML patient)
- Intervention: Venetoclax 400 (drug)
- Intervention: Placebo (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- 23 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 28 sources about other trials or topics are not included.
- The sources reviewed for this edition do not constitute a representative survey of HCP opinion; discussion that does not name the trial may be missing.
- No randomized EVOLVE-1 efficacy or safety outcome is reported in the cited statements. Earlier triplet findings and targeted-doublet results must remain separate from this trial's results.
- No full protocol or exact-trial publication was available to independently check schedule descriptions and detailed methods.
- No matching venetoclax product label was available to provide additional drug-specific safety context.
- Early-phase reports differ in population descriptions, percentages and follow-up detail; their comparability cannot be established, and one MRD denominator and one survival timepoint are unstated.
- One speaker in the IACH discussion remains unidentified. Several named commentators' clinical roles are not independently confirmed, and institutional posts and secondhand reports should not be counted as independent clinician opinions.
- Post and publication dates identify when statements appeared, not necessarily when enrollment, conference presentations or analyses occurred.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, edition 1, accepted 2026-11-21 UTC: current edition

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary 2026-11-21 UTC. No changes.

## Offer

- Size: Focused · 27 verified statements · 2 from 1 confirmed clinician
- Not for sale: This edition is below our minimum for clinicians and sources, so it is not for sale yet. Contact us if you are still interested. No order can be placed for it, by any route; a later edition that reaches the minimum is for sale at its normal price. Follow the change feed: https://www.erudio.com/reports/evolve-1-nct07075016/feed.json
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=evolve-1-nct07075016

## Cite

Erudio Health. EVOLVE-1 (NCT07075016): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 21, 2026. https://www.erudio.com/reports/evolve-1-nct07075016

## Questions

### How much does the EVOLVE-1 report cost?

This edition is below our minimum for clinicians and sources, so it is not for sale yet. Contact us if you are still interested.

### What does the EVOLVE-1 report cover?

27 statements from 6 sources (1 podcast, 2 videos, 3 posts), 2 of them from 1 confirmed clinician, each linked to its source. Commentary checked Nov 21, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.

### Can my AI agent read or buy the EVOLVE-1 report?

Its preview, yes: get_report_card({ "slug": "evolve-1-nct07075016" }) on https://mcp.erudio.com/free, with no sign-in. It cannot be ordered yet. [Connect your AI client](https://www.erudio.com/developers/connect)

### How current is the EVOLVE-1 report?

Edition 1 (version 1.0.0), accepted Nov 21, 2026 UTC; last checked for new commentary Nov 21, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.

## Machine access

- JSON: https://www.erudio.com/reports/evolve-1-nct07075016.json
- Markdown: https://www.erudio.com/reports/evolve-1-nct07075016.md
- Change feed (JSON Feed: new editions and changes): https://www.erudio.com/reports/evolve-1-nct07075016/feed.json
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "evolve-1-nct07075016"}`
